Lucid Diagnostics Inc. (LUCD)

NASDAQ: LUCD · IEX Real-Time Price · USD
3.04
-0.24 (-7.32%)
At close: Aug 17, 2022 4:00 PM
3.19
+0.15 (4.93%)
After-hours: Aug 17, 2022 5:37 PM EDT
-7.32%
Market Cap 117.25M
Revenue (ttm) 500,000
Net Income (ttm) -45.16M
Shares Out 38.57M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 132,307
Open 3.24
Previous Close 3.28
Day's Range 3.00 - 3.27
52-Week Range 1.69 - 13.52
Beta n/a
Analysts Buy
Price Target 8.01 (+163.5%)
Earnings Date Aug 10, 2022

About LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, N... [Read more...]

Industry Medical Devices
IPO Date Oct 14, 2021
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol LUCD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for LUCD stock is "Buy." The 12-month stock price forecast is 8.01, which is an increase of 163.49% from the latest price.

Price Target
$8.01
(163.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)---- $LUCD #LUCD--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diag...

Other symbols: PAVM

Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)---- $LUCD #investing--Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio

NEW YORK--(BUSINESS WIRE)---- $LUCD #checkyourfoodtube--Lucid Diagnostics Inc. announced its subsidiary, LucidDx Labs Inc., launched four new Lucid Test Centers in California, Texas Florida and Ohio.

Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Scree...

NEW YORK--(BUSINESS WIRE)---- $LUCD #ACG--Newly published AGA update supports esophageal precancer screening to prevent esophageal cancer using EsoGuard on samples collected with its EsoCheck.

Lucid Diagnostics' Laboratory Executes Four New Participating Provider Agreements

NEW YORK--(BUSINESS WIRE)---- $LUCD #checkyourfoodtube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-own...

Other symbols: PAVM

Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022

NEW YORK--(BUSINESS WIRE)---- $LUCD #businessupdate--Lucid Diagnostics Inc. announced that the Company will host a business update conference call on Monday, August 15, 2022, at 4:30 PM EDT.

PAVmed Chairman & CEO Lishan Aklog, M.D. Named to Savoy's 2022 Most Influential Black Executives in Corporate America

NEW YORK--(BUSINESS WIRE)---- $LUCD #AfricanAmerican--PAVmed's Chairman & CEO Lishan Aklog, M.D. was selected as one of the Most Influential Black Executives in Corporate America in 2022 by Savoy Magazine

Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech &...

NEW YORK--(BUSINESS WIRE)---- $LUCD #LUCD--Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference

PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO

NEW YORK--(BUSINESS WIRE)---- $LUCD #Biotech--PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO.

Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)---- $LUCD #businessupdate--Lucid Diagnostics provides business update and preliminary first quarter 2022 financial results.

Lucid Diagnostics' Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans

NEW YORK--(BUSINESS WIRE)---- $LUCD #EAC--Lucid's first commercial payer agreement provides in-network access and payment for its EsoGuard® DNA test to over 8 million covered lives.

Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study

Vault CDMS to manage clinical data for trial involving Barrett's esophagus and esophageal adenocarcinoma patients PLEASANTON, Calif., May 4, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announc...

Other symbols: VEEV

Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022

NEW YORK--(BUSINESS WIRE)---- $LUCD #businessupdate--Lucid Diagnostics to hold a Business Update Conference Call on May 11, 2022.

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare L...

NEW YORK--(BUSINESS WIRE)---- $LUCD #EsoCheck--Lucid Diagnostics provides updates on newly published esophageal precancer clinical guideline and proposed Medicare Local Coverage Determination.

Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference

NEW YORK--(BUSINESS WIRE)---- $LUCD #Conference--Dr. Lishan Aklog, Chairman and CEO of Lucid Diagnostics, will participate in a Fireside chat at the 21st Annual Needham Virtual Healthcare Conference.

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

NEW YORK--(BUSINESS WIRE)---- $LUCD #earnings--Lucid Diagnostics provides business update and preliminary fourth quarter and full year 2021 financial results.

PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study

NEW YORK--(BUSINESS WIRE)---- $LUCD #DoD--PAVmed subsidiary Lucid Diagnostics announces launch of VA EsoGuard® study.

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers

NEW YORK--(BUSINESS WIRE)---- $LUCD #Boise--PAVmed subsidiary Lucid Diagnostics launches next phase of Lucid Test Centers in Seattle, Washington, Portland, Oregon, and Boise, Idaho.

Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022

NEW YORK--(BUSINESS WIRE)---- $LUCD #Diagnostics--Lucid Diagnostics to hold a business update conference call on March 28, 2022.

Lucid Diagnostics to Participate in the LSI USA '22 Emerging Medtech Summit

NEW YORK--(BUSINESS WIRE)---- $LUCD #CEO--Lucid Diagnostics to participate in the LSI USA '22 Emerging Medtech Summit.

PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth

NEW YORK--(BUSINESS WIRE)---- $LUCD #Diagnostics--PAVmed subsidiary Lucid Diagnostics launches LucidDx Labs to accommodate EsoGuard testing growth.

PAVmed Appoints Shaun O'Neil as Chief Operating Officer

NEW YORK--(BUSINESS WIRE)---- $LUCD #COO--PAVmed appoints Shaun O'Neil as Chief Operating Officer, overseeing corporate operations and commercial activities across PAVmed and its subsidiaries.

Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors

NEW YORK--(BUSINESS WIRE)---- $LUCD #BOD--PAVmed appoints prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors.

Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics...

NEW YORK--(BUSINESS WIRE)---- $LUCD--Lucid Diagnostics to participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference.

PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations Team

NEW YORK--(BUSINESS WIRE)---- $LUCD--PAVmed and Lucid Diagnostics welcome new full-time investor relations team.